SYNGENEIC
& XENOGRAFT
MODELS
DOMESTIC QUALITY. EXCEPTIONAL VALUE.
Rincon runs high-quality in vivo cancer efficacy studies at our U.S. facilities, keeping your work close, protecting your IP, and making communication direct and easy. We bring the scientific experience you’d expect from a major CRO without all the layers and overhead.
DIRECT ACCESS
Work directly with the PhD running your study—not a rotating account manager. We stay responsive, flexible, and hands-on throughout the study.
SINCE 2013, OUR TEAM HAS PERFORMED THOUSANDS OF:
TUMOR
MODELS
TOLERABILITY
STUDIES
PK & PD
STUDIES
WHY RINCON?
We've worked in pharma, academia, and some of the world's largest CROs.
We built Rincon around a simpler model: experienced scientists, direct communication, fast execution, and less unnecessary overhead.
Your study is run at our U.S.-based facilities, and you'll work directly with the scientists doing the work.
For high-quality xenograft and syngeneic studies, you won't find better value.
CANCER EFFICACY
MODELS
Rincon specializes in xenograft and syngeneic cancer efficacy studies.
We can work from a client-provided protocol or help develop the study design based on your model, compound, and research objectives.
​
Xenograft Models
Human tumor models in immunocompromised mice or rats, with a growing library of validated cell lines across a wide range of tumor types.
​
Syngeneic Models
Immunocompetent mouse models for evaluating immuno-oncology agents, combination therapies, and other cancer treatments.
​
Additional capabilities include:
​
-
Fluorescent and luminescent imaging
-
Pharmacokinetic studies
-
MTD and tolerability studies
-
Tumor and organ collection
-
Histology and animal pathology
-
Pharmacodynamic assays, including ELISA, Mesoscale/Luminex, PCR, flow cytometry, and sequencing
-
Complementary cell-based in vitro assays supporting in vivo studies
​
​
Need something outside the standard study design? Talk to us.
QUOTE REQUEST FORM
xenograft or syngeneic studies
Tell us about your planned study.
We'll typically respond within one business day
AVAILABLE MODELS
Model list may be filtered by model type and organ
Cell line | Organ | Model Type | Mutations | Weeks from stratification to termination (average) | Growth Curve |
|---|---|---|---|---|---|
22Rv1 | Prostate | Xenograft | KMT2D, PIK3CA, TP53 | 5 | |
4T1 | Breast | Syngeneic | Unavailable | 4 | |
786-0 | Renal | Xenograft | PTEN, TERT, TP53, VHL | N/A | |
A-375 | Skin | Xenograft | BRAF, CDKN2A, TERT | 4 | |
A20 | Blood | Syngeneic | Unavailable | N/A | |
A431 | Skin | Xenograft | TP53, EGFR-PPARGC1A fussion | N/A | |
A498 | Renal | Xenograft | PIK3CB, VHL | 5 | |
A549 | Lung | Xenograft | KRAS, STK11, TP53 | 6 | |
A673 | Sarcoma | Xenograft | BRAF, TP53, EWS-FLI1 fusion | 3 | |
AB22 | Lung | Syngeneic | CDKN2A | N/A | |
AGS | Gastric | Xenograft | CTNNB1, KRAS, PIK3CA, TP53 | 6 | |
B16-F10 | Skin | Syngeneic | Unavailable | 2 | |
BxPc-3 | Pancreatic | Xenograft | BRAF, KRAS, TP53 | 7 | |
CHLA-06 | Brain | Xenograft | TP53 | 6 | |
CT26 | Colon | Syngeneic | KRAS | 2.5 | |
CT26.CL25 | Colon | Syngeneic | KRAS | 2.5 | |
Caki-1 | Renal | Xenograft | RB1 | 4 | |
Cloudman S91 | Skin | Syngeneic | Unavailable | N/A | |
Colo-205 | Colon | Xenograft | APC, BRAF, CTNNB1, TP53 | 2.5 | |
Colon-26 (MC26) | Colon | Syngeneic | Unavailable | 4 | |
D4M3A | Skin | Syngeneic | Unavailable | 2 | |
DLD-1 | Colon | Xenograft | APC, ACVR2A, B2M, EP300, KRAS, PIK3CA, TGFBR2, TP53 | 4 | |
DU-145 | Prostate | Xenograft | CDKN2A, RB1, STK11, TP53 | 6 | |
EMT6 | Breast | Syngeneic | Unavailable | 5 | |
ES-2-luc | Ovarian | Xenograft | BRAF, PALB2, TERT, TP53 | 3.5 | |
HCC1954 | Breast | Xenograft | PIK3CA, TP53, CLTC-VMP1 fusion | 7 | |
HCT-116 | Colon | Xenograft | ACVR2A, BRCA2, CDKN2A, CTNNB1, EP300, KRAS, PIK3CA, PPM1D, TGFBR2, TP53 | 5 | |
HT-29 | Colon | Xenograft | APC, BRAF, PIK3CA, SMAD4, TP53 | N/A | |
HuCCT1 | Bile Duct | Xenograft | KRAS, MSH6, TP53 | 5 | |
Huh-7 | Liver | Xenograft | KDR, POLD3, TERT, TP53 | 4 | |
JIMT-1 | Breast | Xenograft | PIK3CA, TP53 | 8 | |
JeKo-1 | Blood | Xenograft | TP53 | 5 | |
LASCPC-01 | Prostate | Xenograft | Unavailable | 3 | |
LNCaP | Prostate | Xenograft | AR, MEN1, PIK3R1, PTEN, TP53 | 4 | |
Lewis Lung LLC1 | Lung | Syngeneic | Unavailable | 3 | |
MBT-2 | Bladder | Syngeneic | Unavailable | 5.5 | |
MC38 | Colon | Syngeneic | Unavailable | 4 | |
MDA-MB-231 | Breast | Xenograft | CDKN2A, CDKN2B, BRAF, KRAS, TERT, TP53 | 4 | |
MDA-MB-468 | Breast | Xenograft | PTEN, RB1, TP53 | N/A | |
MIAPaCa-2 | Pancreatic | Xenograft | KRAS, TP53 | 8 | |
MOLM-13 | Blood | Xenograft | FLT3, KMT2A-MLLT3 fusion | 14 | |
NCI-H1703 | Lung | Xenograft | CDKN2A, TP53 | 3 | |
NCI-H1975 | Lung | Xenograft | EGFR, PIK3CA, TP53 | 6 | |
NCI-H460 | Lung | Xenograft | KRAS, PIK3CA, STK11, TP53 | 5 | |
NCI-N87 | Gastric | Xenograft | ERBB3, TP53 | 6 | |
OCI-AML-3 | Blood | Xenograft | DNMT3A, NRAS, NPM1 | 2 | |
OCI-Ly1 | Blood | Xenograft | Unavailable | N/A | |
OVCAR8 | Ovarian | Xenograft | CTNNB1, ERBB2, KRAS, TP53 | 8 | |
P388 | Blood | Syngeneic | Unavailable | N/A | |
PANC-1 | Pancreatic | Xenograft | KRAS, TP53 | 3 | |
PC-3 | Prostate | Xenograft | TP53 | 4 | |
SK-BR-3 | Breast | Xenograft | TP53 | 4 | |
SK-N-FI | Brain | Xenograft | NF1, TP53 | 4 | |
SK-N-MC | Sarcoma | Xenograft | TP53, EWS-FLI1 fusion | 3 | |
SK-OV-3 | Ovarian | Xenograft | APC, FBXW7, PIK3CA, TP53 | 10 | |
SKM-1 | Blood | Xenograft | ASXL1, BCORL1, EZH2, KRAS, TP53 | 3 | |
SU-DHL-16 | Blood | Xenograft | Unavailable | 4 | |
SW480 | Colon | Xenograft | APC, KRAS, TP53 | 4 | |
TT | Thyroid | Xenograft | RET, TBX3 | 4 | |
U-87MG | Brain | Xenograft | Unavailable | 3 | |
U118-MG | Brain | Xenograft | IDH1, PTEN, TP53 | 6 | |
UM-UC-3 | Bladder | Xenograft | KRAS, PARD3B, TERT, TP53 | N/A | |
VcAP | Prostate | Xenograft | MLH1, TP53, TMPRss2-ERG fusion | N/A | |
WITT (SK-Cha-1) | Bile Duct | Xenograft | Unavailable | N/A | |
WM164 | Skin | Xenograft | BRAF | 6 | |
YAPC | Pancreatic | Xenograft | KRAS, TP53 | N/A |
*Don't see your model? Additional cell lines and custom models are possible.
Contact us to discuss your study.
MEET OUR SCIENTIFIC DIRECTOR
Bret Stephens, PhD
Bret brings more than 20 years of in vivo biology and cancer drug-discovery experience spanning pharmaceutical and academic research.
​
At Rincon, Bret remains directly involved in study design and execution—part of our approach of giving clients direct access to the scientists responsible for their work.
Dr. Stephens received his PhD in Molecular Biology from the University of Arizona.
Previous to joining Rincon Bio, Dr. Stephens worked at Sumitomo Dainippon Pharma Oncology (Tolero Pharmaceuticals), Huntsman Cancer Institute (University of Utah), and the BioDesign Institute (Arizona State University), where he focused on cancer small molecule drug development.
ABOUT US
Founded in 2013, Rincon Bio is a U.S.-based preclinical CRO focused on in vivo cancer efficacy studies, including xenograft and syngeneic models.
​
Our scientists have worked in pharma, academia, and major CROs and bring experience from thousands of in vivo studies for pharmaceutical, biotechnology, and academic organizations across North America, Europe, and Asia.
​
We intentionally operate with a small, experienced team. That means less bureaucracy, lower unnecessary overhead, and direct communication with the scientists running your study. It also gives us the flexibility to respond quickly when the science calls for a change.
​
All animal studies are run at our U.S.-based facilities, helping protect your IP and keeping communication straightforward from study design through final report.
Email: info@rinconbio.com
Tel: 760-713-6613
​
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
​
​